GlassScriptPhysician profile
Raju Singla
NPI 1043204407
$8,097.03
in general payments reported to CMS, 2019-2025
42 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $714 · 2021: $1,735 · 2022: $1,683 · 2023: $1,487 · 2024: $1,348 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,964.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,395.13 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $826.51 | 2020-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $631.07 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $617.99 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $534.67 | 2021-2025 | |
| Abbvie INC. | $360.51 | 2021-2025 | Viberzi, Linzess, Vraylar |
| Janssen Pharmaceuticals, INC | $339.73 | 2020-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.49 | 2021-2025 | Jardiance, Spiriva Respimat |
| Lilly USA, LLC | $268.57 | 2020-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $227.90 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $222.37 | 2020-2025 | Strensiq |
| Astellas Pharma US INC | $219.26 | 2021-2022 | |
| Mylan Specialty L.P. | $211.55 | 2021-2023 | Yupelri |
| Phathom Pharmaceuticals, INC. | $202.34 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $198.16 | 2020-2024 | Eliquis |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $169.00 | 2020-2021 | |
| Verona Pharma, INC. | $149.66 | 2025 | Ohtuvayre |
| Paratek Pharmaceuticals, INC. | $134.49 | 2021-2023 | Nuzyra |
| Exact Sciences Corporation | $128.20 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $102.41 | 2022-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $91.90 | 2023-2025 | Gemtesa, Myfembree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.84 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $70.30 | 2022-2023 | Gvoke Hypopen |
| Sunovion Pharmaceuticals INC. | $61.71 | 2022 | |
| Amgen INC. | $58.06 | 2022-2023 | Repatha |
| Nestle Healthcare Nutrition INC. | $47.05 | 2023 | |
| Dexcom, INC. | $46.54 | 2022-2023 | Dexcom G6 Transmitter |
| Philips North America LLC | $45.54 | 2023-2024 | (Ak6) Vest Therapy |
| Kowa Pharmaceuticals America, INC. | $45.00 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $43.43 | 2023 | Inpefa |
| Abbott Laboratories | $42.00 | 2022 | |
| Shield Therapeutics INC | $39.71 | 2023-2024 | Accrufer |
| Viatris Specialty LLC | $30.51 | 2025 | Yupelri |
| Medtronic, INC. | $23.70 | 2025 | Intellis Adaptivestim |
| Idorsia Pharmaceuticals US INC | $22.75 | 2023 | Quviviq |
| Indivior INC. | $20.12 | 2023 | Perseris |
| Covis Pharma Gmbh | $18.37 | 2021 | |
| Biodelivery Sciences International, INC. | $16.51 | 2021 | |
| Vanda Pharmaceuticals INC. | $14.33 | 2022 | |
| Nabriva Therapeutics, Plc | $14.25 | 2022 | |
| Smith+Nephew, INC. | $13.99 | 2021 | |
| Allergan, INC. | $11.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raju Singla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.